Legal & General Group
STLN

Legal & General Group’s Starling Oncology STLN Stock Holding History

Legal & General Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.7K Buy
7,497
+977
+15% +$4.1K ﹤0.01% 2836
2026
Q1 		$20K Sell
6,520
-1,204
-16% -$3.69K ﹤0.01% 2962
2025
Q4 		$27.5K Buy
7,724
+1,148
+17% +$4.26K ﹤0.01% 2908
2025
Q3 		$22.9K Hold
6,576
– – ﹤0.01% 2986
2025
Q2 		$13.5K Buy
+6,576
New +$16.4K ﹤0.01% 3168
2023
Q2 		– Sell
-4,141
Closed -$2.81K – 3513
2023
Q1 		$2.81K Hold
4,141
– – ﹤0.01% 3338
2022
Q4 		$6.83K Hold
4,141
– – ﹤0.01% 3322
2022
Q3 		$19K Buy
4,141
+534
+15% +$3.14K ﹤0.01% 3222
2022
Q2 		$18K Buy
+3,607
New +$26.3K ﹤0.01% 3281

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Legal & General Group's STLN Position: Q2 2026 in Review

Legal & General Group increased its Starling Oncology (STLN) stake by 15% in Q2 2026, buying an estimated $4.1K and bringing the position to 7,497 shares worth $40.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2836.

Legal & General Group first reported a position in STLN in Q2 2022 and has held it in 9 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Legal & General Group held 7,497 shares of Starling Oncology worth $40.7K as of Q2 2026.
  • Legal & General Group bought 977 Starling Oncology shares in Q2 2026, an estimated $4.1K.
  • Starling Oncology made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2836 holding.
  • Legal & General Group first reported a position in Starling Oncology in Q2 2022 and has held it in 9 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.